The use of CAR-T cells in glioblastoma is based on targeting the tumor-specific or tumor-enriched antigens like IL-13Rα2, EGFR/EGFRvIII, HER2, CD70, B7-H3, and CD133/CD44. This evidence concerns the gene PROM1 and glioblastoma.